Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. (April 2015)

• Record Type: Journal Article
• Authors: Helton, Sarah G; Lohoff, Falk W
• Is Part Of: Pharmacogenomics. Volume 16:Number 5(2015)
• Page Start: 541
• Page End: 553
• Publication Date: 2015-04
• Subjects: antidepressants -- anxiety disorders -- biomarker -- genetics -- pharmacogenetics -- serotonin -- treatment response; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.15.15
• Languages: English
• ISSNs: 1462-2416

Abstract

While antidepressants are widely used to treat major depressive disorder and anxiety disorders, only half of the patients will respond to antidepressant treatment and only a third of patients will experience a remission of symptoms. Identification of genetic biomarkers that predict antidepressant treatment response could thus greatly improve current clinical practice by providing guidance on which drug to use for which patient. Most antidepressant drugs for the treatment of depression and anxiety disorders have effects on the serotonergic neurotransmitter system; thus, genetic polymorphisms in the genes involved in this pathway represent logical candidates for investigation. This article reviews recent findings on the pharmacogenetics of antidepressant drugs with a focus on serotonergic pathway polymorphisms and discusses future clinical applications.